Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Msg# 1214--one additional anti-IGFR antibody (from Amgen) that I did not mention previously.
http://www.amgen.com/investors/pipe_AMG479.html
Not sure pharma. I just came across this patent. The more I look at patents/IP issues, the more confused I get. Imclone's IP position has not deterred others from developing anti-EGFR antibodies. This is in contrast to Imclone's IP position on anti-VEGFR antibodies. Imclone's strong IP position enabled them to gain rights to the UCB antibody in addition to Imclone's anti-VEGFR antibody. Any comments on what Imclone did right with anti-VEGFR (that they did not do with EGFR)?
New Anti-EGFR patent application from Genentech.
http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FP...
Does anyone else find it surprising that that Amgen and Yeda reached an agreement so soon?
Yeda Patent clarification/question. Base on my read, Imclone’s press release puts forth 2 contradictory ideas. Am I missing something?
1. Imclone disagrees with today’s decision and intends to appeal. These statements suggest that the patent has value and Imclone intends to fight for it.
2. ImClone Systems also believes that the consequence of the decision transferring inventorship to Yeda invalidates any claims in the patent under current patent law. Transfer of ownership invalidates the patent. These statements suggest that patent would have no value to Imclone or anyone else.
Any comment would be appreciated
Thanks Corky. And many thanks for all of your contributions to this board.
Corky. What do you expect to take place at the annual meeting?
Re: MSG# 838. In light of the patent ruling today, does anyone have any comments about Imclone's patent cited in msg#838.
Question for Pharma. Could you clarify your definition of basic science research. Are you saying that Imclone should only spend money on clinical trials?
I would describe the RON-kinase paper as an example of translational research (the type of researh that Imclone and other developmental stage biotechs should be doing--in my opinion). Basically, Imclone generated anti-RON antibodies, tested the effects on down stream signaling pathways, demonstrated in vitro effects on cells, and most importantly demonstated in vivo efficacy in mice.
In general, I have been impressed with the quality of the papers that Imclone has produced in recent years, and I think that the early stage pipeline is an underappreciated.
Any comments are appreciated. Thanks for your contributions to the board.
Biophud
New clinical trial for EGFR inhibitor (Tarceva) skin tox.
http://clinicaltrials.gov/ct/show/NCT00343187?order=3
Anti-RON kinase antibodies--New research from Imclone.
http://cancerres.aacrjournals.org/cgi/content/abstract/66/18/9162
Question for the board re: Sep 15 - 17
SCIENTIFIC CONFERENCE:
International Oncology Network
GI & Lung Symposium
Has anything come out of this conference?
Thanks for the clarification, and thanks for all the info that you provide to the board.
Re: post 1337/CDP-791.
Jbog. Just to clarify. Are you saying that the CDP-791's phase II trial results are scheduled to be announced 1st quarter 07?
Thanks in advance.
Re: Jbog Msg #1213. In addition to Pfizer, SGP, Immunogen, and Merck (USA) have anti-Igfr antibodies in the works. All the more reason for Imclone to partner and move forward with development of their anti-IGFR antibody. Here are some links if anyone is interested.
Schering Plough (I think that this is a Medarex AB)
Inhibition of insulin-like growth factor-I receptor (IGF-IR) signaling and tumor cell growth by a fully human neutralizing anti-IGF-IR antibody.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&l...
Measurement of the functional affinity constant of a monoclonal antibody for cell surface receptors using kinetic exclusion fluorescence immunoassay.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&l...
Neutralizing anti-insulin-like growth factor receptor 1 antibodies inhibit receptor function and induce receptor degradation in tumor cells.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&l...
Immunogen
http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FP...
Merck (USA)
http://www.cipf.com/collabof.htm
New paper. In vivo detection of head and neck cancer orthotopic xenografts by immunofluorescence.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&l...
Mechanism of resistance to small molecule EGFR inhibitors.
http://www.eurekalert.org/pub_releases/2006-09/dci-sum090506.php
Received annual report today.
New anti EGFR antibody conjugate. Anyone have any info on this?
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&l...
New Cancer Research article from Imclone. Anti-VEGFR for soft tissue sarcomas.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&l...
New research on RON kinase antibodies.
Imclone has an early stage program targeting RON kinase.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&l...
New Pubmed articles related to Erbitux and panitumumab.
A phase I study of cetuximab/paclitaxel in patients with advanced-stage breast cancer.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&l...
Role of panitumumab in the management of metastatic colorectal cancer.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&l...
Cetuximab-induced hypomagnesemia in patients with colorectal cancer.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&l...
New Lung trial posted.
http://www.clinicaltrials.gov/ct/show/NCT00368992?order=2
New Genentech method patent-->Combined use of EGFR inhibitors + Trail-R agonists. I would like to see Imclone move forward with clinical trials that use a combination of targeted therapies (Erbitux+ other biologically targeted drugs).
http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FP...
New publication on EGFR inhibition and its synergy with chemo/radiation. Internalization of EGFR may be a key event.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&l...
New publication. Cetuximab Therapy in Glioblastoma Multiforme.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&l...
New trial. Erbitux + Herceptin in breast cancer
http://clinicaltrials.gov/ct/show/NCT00367250?order=3
New review article from Imclone.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&l...
Here is a patent that I have come across regarding Humanized EGFR antibodies. Wanted to get opinions on its significance (if any). My read of this patent is that it covers CDR-grafted "humanized" derivatives of C225. What product is Imclone trying to protect with this patent? (It is unclear to me). C225 is chimeric and IMC-11F8 is a fully human antibody derived from phage-display. It is my understanding that the eMerck antibody was humanized using this method (if I am wrong please let me know). Would appreciate any insite that you guys have.
http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPT...
P.S. I am a long time IMCL long and a long term lurker on the Yahoo Board. I appreciate all the good info on the board.